RxDoctor Payments Data

Amber Lowery, NP

Family · Longview, TXNPI 1154832681

Payments from drug & device makers

$7,367in general payments, 2019–2025

Across 365 payments — averaging $20.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$780
  • AbbVie$552
  • Xeris Pharmaceuticals, Inc.$550
  • Corcept Therapeutics$545
  • Novo Nordisk$482
  • Tandem Diabetes Care, Inc.$375
  • plus $4K from 38 others

What the payments were for

  • Food & beverage$7,355100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,367 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$119,620
Medicare patients
353
Services billed
3,452

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide149$231,582
MounjaroTirzepatide95$139,774
JardianceEmpagliflozin69$68,225
TrulicityDulaglutide39$56,170
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/738$38,132
Humalog Kwikpen U-100Insulin Lispro76$28,394
Novolog FlexpenInsulin Aspart58$23,151
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog23$22,734
Fiasp FlextouchInsulin Aspart (Niacinamide)19$21,259
Tresiba Flextouch U-100Insulin Degludec21$15,886
Lantus SolostarInsulin Glargine,hum.Rec.Anlog82$15,706
EliquisApixaban14$14,190
JanuviaSitagliptin Phosphate13$13,396
Insulin Lispro Kwikpen U-100Insulin Lispro21$9,882
Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt16$8,680

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Fiasp, Novolog$482$247,481184 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro$780$205,191195 claims
Boehringer IngelheimJardiance$181$68,22569 claims
PfizerEliquis$367$14,19014 claims
MerckJanuvia$127$13,39613 claims
AbbVieLinzess, Synthroid$552$9,65042 claims
GSKTrelegy Ellipta$344$7,30211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.

Other family in Longview

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →